In the News
January 2, 2020 | Duke Engineering News
Collaborative work using CRISPR genome editing to address the burden of genetic neuromuscular diseases flourishes across Duke.
December 13, 2019 | Duke Engineering News
Combining a skin-level glass window with a gut-stabilizing magnet, researchers get a view into the colon of a live animal
November 19, 2019
Each year, the Web of Science Group identifies the world’s most influential researchers. The select few who have been most frequently cited by their peers over the last decade. In 2019, fewer than 6,300, or 0.1%, of the world's researchers, across 21 research fields, have [...]
November 15, 2019 | BioSpace
Sarepta Therapeutics, Inc., the leader in precision genetic medicine for rare diseases, and StrideBio, Inc., a leading developer of novel adeno-associated viral (AAV) based gene therapies, will collaborate to develop in vivo AAV-based therapies for up to eight central nervous system and neuromuscular targets.
November 4, 2019 | Duke Engineering News
A Q&A with Charles Gersbach
October 14, 2019 | Duke GCB News
DARPA recently awarded a grant to a Duke team for a multifaceted research effort aimed at temporarily regulating gene expression using RNA-based techniques that could help protect against pandemic flu by boosting lung resistance to the virus, attacking the virus directly, enhancing the immune system response and improving the effects of existing vaccines.
September 30, 2019 | Duke Engineering News
Spanning Duke University and Duke Health, the Center for Advanced Genomic Technologies will use homegrown tools and techniques to discover potential therapies for human diseases from autism to cancer to schizophrenia
September 23, 2019 | Duke Engineering News
In a recent study, Charles Gersbach and Adrian Oliver, a post-doctoral fellow in the Gersbach lab who led the project, describe how they successfully harnessed Class 1 CRISPR systems to turn target genes on and off and edit the epigenome in human cells for the first time.
April 23, 2019 | Illumina
Celldom, cofounded by Kris Wood, Zachary Forbes, and Bejamin Yellen, is a research tools company developing next generation, single-cell analysis technology to advance research and drug discovery and development by illuminating diversity in cell populations.
April 15, 2019 | Duke Engineering News
An added piece of RNA could improve the precision of CRISPR 50-fold.
February 26, 2019 | NIH Director's Blog
The Gersbach lab's latest work on gene editing for Duchenne Muscular Dystrophy was highlighted in the NIH Director's Blog.
February 18, 2019 | Duke Engineering News
Genetic edits and protein restoration in mouse models of Duchenne muscular dystrophy remain viable one year after single CRISPR treatment.
January 1, 2019 | The Scientist
Using CRISPR and other tools, the Gersbach lab and other researchers are modifying DNA methylation, histone marks, and other modifiers of gene expression to understand how they affect health and disease.